Hyloris Pharmaceuticals SA
EBR:HYL.BR
4.52 (EUR) • At close November 12, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) EUR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||
| Current Assets: | ||||||||
| Cash & Cash Equivalents
| 30.406 | 43.457 | 50.012 | 64.399 | 0.205 | 2.687 | 0.271 | 0.224 |
| Short Term Investments
| 0.499 | 0.469 | 0.528 | 0.007 | 0 | 0 | 0.01 | 0.013 |
| Cash and Short Term Investments
| 30.406 | 43.926 | 50.54 | 64.406 | 0.205 | 2.687 | 0.281 | 0.237 |
| Net Receivables
| 4.308 | 5.127 | 2.321 | 0.253 | 0.333 | 0.154 | 0.186 | 0 |
| Inventory
| 0 | -0.469 | 0 | 0 | 3.2 | 0.997 | 0 | 0 |
| Other Current Assets
| 0.594 | 2.217 | 1.098 | 1.954 | 0.001 | -0.001 | 0.035 | 0.001 |
| Total Current Assets
| 35.308 | 50.801 | 53.959 | 66.613 | 3.739 | 3.837 | 0.502 | 0.285 |
| Non-Current Assets: | ||||||||
| Property, Plant & Equipment, Net
| 2.153 | 1.06 | 0.295 | 0.176 | 0.098 | 0.149 | 0.035 | 0.057 |
| Goodwill
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets
| 3.828 | 3.607 | 2.944 | 2.381 | 2.138 | 3.949 | 3.825 | 0 |
| Goodwill and Intangible Assets
| 3.828 | 3.607 | 2.944 | 2.381 | 2.138 | 3.949 | 3.825 | 1.001 |
| Long Term Investments
| 6.392 | 4.479 | 4.004 | 0.005 | 0.009 | 0.012 | -0.007 | -0.011 |
| Tax Assets
| -1.554 | -4.479 | 0.528 | 0 | -0.009 | -0.012 | 0 | 0 |
| Other Non-Current Assets
| 1.554 | 6.396 | 1.714 | 0.007 | 0.009 | 0.013 | 0.01 | 0.013 |
| Total Non-Current Assets
| 12.373 | 11.063 | 9.485 | 2.569 | 2.245 | 4.111 | 3.863 | 1.06 |
| Total Assets
| 47.681 | 61.864 | 63.444 | 69.182 | 5.983 | 7.948 | 4.365 | 1.345 |
| Liabilities & Equity: | ||||||||
| Current Liabilities: | ||||||||
| Account Payables
| 3.195 | 2.302 | 2.622 | 1.595 | 2.866 | 2.056 | 1.77 | 0.976 |
| Short Term Debt
| 3.441 | 0.138 | 11.88 | 0.455 | 13.174 | 0.052 | 0.02 | 0.021 |
| Tax Payables
| 0 | 0 | 0.349 | 0.047 | 0.047 | 0.051 | 0.051 | 0.049 |
| Deferred Revenue
| 0.007 | 0 | 0 | 0.081 | 0.107 | 0 | 0.081 | 0.064 |
| Other Current Liabilities
| -3.079 | 1.03 | -2.495 | -1.641 | -2.911 | -1.114 | -1.822 | -1.024 |
| Total Current Liabilities
| 6.759 | 5.772 | 14.978 | 2.132 | 16.149 | 3.101 | 1.87 | 1.062 |
| Non-Current Liabilities: | ||||||||
| Long Term Debt
| 0.344 | 0.747 | 0.409 | 7.991 | 0.022 | 9.309 | 6.781 | 2.471 |
| Deferred Revenue Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities Non-Current
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities
| 1.509 | 0.3 | 0.001 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Liabilities
| 1.853 | 1.047 | 0.41 | 7.991 | 0.022 | 9.309 | 6.781 | 2.471 |
| Total Liabilities
| 8.612 | 6.819 | 15.388 | 10.123 | 16.171 | 12.41 | 8.651 | 3.533 |
| Equity: | ||||||||
| Preferred Stock
| 0.336 | 2.362 | 0.96 | 1.537 | 0 | 0 | 0 | 0 |
| Common Stock
| 0.14 | 0.14 | 0.129 | 0.129 | 0.089 | 0.089 | 0.079 | 0.067 |
| Retained Earnings
| -80.761 | -64.246 | -54.805 | -43.226 | -36.081 | -28.097 | -24.324 | -20.669 |
| Accumulated Other Comprehensive Income/Loss
| -1.823 | -2.362 | -0.96 | -1.537 | 1.822 | -0.056 | -0.04 | 0 |
| Other Total Stockholders Equity
| 121.177 | 119.151 | 102.732 | 102.156 | 23.982 | 25.818 | 19.999 | 18.414 |
| Total Shareholders Equity
| 39.069 | 55.045 | 48.056 | 59.059 | -10.188 | -2.246 | -4.286 | -2.188 |
| Total Equity
| 39.069 | 55.045 | 48.056 | 59.059 | -10.188 | -4.462 | -4.286 | -2.188 |
| Total Liabilities & Shareholders Equity
| 47.681 | 61.864 | 63.444 | 69.182 | 5.983 | 7.948 | 4.365 | 1.345 |